Latest Conference Coverage

Benefits Observed With Second Dose of Eptinezumab in Chronic, Episodic Migraine

The percent change in monthly migraine days across weeks 1 to 12 and scores on Headache Impact Test were precursors to suboptimal response to eptinezumab, prompting the need for a second dose.

Assessing the Correlations With Sleep Issues and Risk of Dementia: Ruth Benca, MD, PhD

The professor and chair of Psychiatry & Human Behavior at Wake Forest School of Medicine provided insight on the signs and risks associated with sleep disorders and Alzheimer disease. [WATCH TIME: 3 minutes]

Ubrogepant Sustains Efficacy, Safety in Combination With OnabotulinumtoxinA

At 2- and 4-hours post dose, return to normal function was achieved by 30.1% and 52.1% of participants for their first 10 ubrogepant-treated attacks.

Schooling Changes During COVID-19 Pandemic Suggestive of Improved Headache Coping Ability for Pediatric Patients

Headache frequency remained the top driver of higher disability scores, but opposing to prior findings, school versus summer was not a significant predictor of disability, suggesting that pandemic schooling changes affected coping abilities to cause less disability.

Hypothesis and Reasoning of the DISCO-MS Study

Advantages With Extended Release Glatiramer Acetate in Relapsing, Progressive MS: Ehud Marom

The president and chief executive officer of Mapi Pharma discussed the differences and additional benefits from glatiramer acetate depot, a new intramuscular extended-release version of the known multiple sclerosis medication. [WATCH TIME: 4 minutes]

The Incidence of and Difficulties in Defining Status Migrainosus: Rashmi Halker Singh, MD, FAHS, FAAN

The associate professor of neurology at Mayo Clinic and member of the board of directors at AHS shared her perspective on the importance of collecting more information on status migrainosus and the need to develop a better approach and definition. [WATCH TIME: 3 minutes]

The MiCOAS Project and the Importance of Patient-Reported Outcomes in Migraine

The director of the Montefiore Headache Center spoke about the Migraine Clinical Outcome Assessment System project and the need for better patient-reported outcome measures in migraine clinical care.

Anecdotal Evidence and the Need for Trials of Psychedelics in Headache Disorders: Bryan Roth, MD, PhD

The Michael Hooker Distinguished Professor and director of the NIMH psychoactive drug screening program at University of North Carolina School of Medicine discussed the need for large placebo-controlled trials of psychedelics in migraine disorders. [WATCH TIME: 4 minutes]

Rimegepant Is Well-Tolerated and Safe for Migraine Over 1 Year With Every-Other-Day Dosing

Patients in the open-label extension also showed limited need for acute treatment with rimegepant (Nurtec ODT; Biohaven Pharmaceuticals), as more than 80% of patients took 16 or fewer total tablets over the 28-day period.

The Need for Effective Treatments for Status Migrainosus: Matthew Robbins, MD

The neurologist at Weill Cornell Medicine and NewYork-Presbyterian Hospital offered his insight into the hot topics at the American Headache Society Annual Scientific Meeting, including a presentation on the prevalence of status migrainosus. [WATCH TIME: 4 minutes]

Monoclonal Antibodies, Gepants, and Triptans Show Little Differences in Possible Response Predictive Variables

A retrospective review of more than 1000 electronic medical records suggests that for those with migraine, the presence of neck pain, anxiety, depression, and insomnia show no comparative differences in treatment response predictability.

Assessing Psychedelics for Therapeutic Potential in Cluster Headache: Bryan Roth, MD, PhD

The Michael Hooker Distinguished Professor and director of the NIMH psychoactive drug screening program at University of North Carolina School of Medicine shared his insight into his keynote address at the American Headache Society Annual Scientific Meeting. [WATCH TIME: 8 minutes]

Remaining Questions Surrounding COVID-19 Vaccines in MS

Lingering Challenges With Assessing, Treating Sleep Problems in Alzheimer Disease: Ruth Benca, MD, PhD

The professor and chair of Psychiatry & Human Behavior at Wake Forest School of Medicine discussed the need for improved tools to evaluate and treat sleep disorders in patients with Alzheimer disease. [WATCH TIME: 3 minutes]

Expanding Knowledge About Advantages of Low-Sodium Oxybates: Richard Bogan, MD, FCCP, FAASM

The associate clinical professor at the University of South Carolina School of Medicine discussed how JZP-258’s clinical profile has expanded since its original approval for narcolepsy, and whether it makes sense for all patients to consider. [WATCH TIME: 3 minutes]

Insomnia in Young Adulthood Associated With Increased Risk of Cardiovascular Disease, Endothelial Dysfunction

What Is Known About COVID-19 Vaccine Response in MS

Treatment Effect of Low-Sodium Oxybate in Idiopathic Hypersomnia Based on ESS, IHSS Scores: Richard Bogan, MD, FCCP, FAASM

The associate clinical professor at the University of South Carolina School of Medicine provided context on 2 analyses presented at SLEEP 2022 that highlighted JZP-258’s impact in patients with idiopathic hypersomnia. [WATCH TIME: 2 minutes]

Moderate-to-Severe Post-COVID-19 Sleep Disturbances Common, Especially in Black Individuals

Patients with moderate-severe compared with normal-to-mild sleep disturbances had worse GAD-2 questionnaire scores, PHQ-2 scores, and PROMIS fatigue scores with no difference in age, sex, or hospitalization due to COVID-19.

Understanding Race-Gender Associations in Insomnia Patterns and Late-Life Memory Trajectories: Afsara Zaheed

The graduate student at the University of Michigan provided insight on her study examining longitudinal patterns of difficulty initiating sleep and their associations with subsequent memory trajectories among different races and genders. [WATCH TIME: 3 minutes]

NeuroVoices: Jens Kuhle, MD, on Evobrutinib’s Association With Neurofilament Light Levels

The head of the MS Center at the University of Basel discussed an analysis presented at CMSC’s Annual Meeting, focusing on the effects of BTK inhibitor evobrutinib on neurofilament light levels.

Unanswered Questions About MS Stem Cell Transplantation

PennPALS Automated Text Messaging System Helps Identify Risk of Nonadherence to PAP Therapy

After 30 days of the PennPALS system, 70.8% of the remaining 24 patients were adherent to treatment or were using their PAP machine for at least 4 hours/night on average over the last 7 days.

Understanding Brain Differences in MRI Markers, Sleep-Disordered Breathing of Latino Individuals: Alberto Ramos, MD, MSPH, FAASM

The director of the Sleep Disorders program at the University of Miami discussed his research regarding the association of sleep disordered breathing and total brain volumes in Latino individuals. [WATCH TIME: 3 minutes]

Understanding the Association Between Obstructive Sleep Apnea Treatment and Dementia Risk: Galit L. Dunietz, PhD, MPH

The assistant professor of neurology at the University of Michigan provided context on a previous study which suggested that treatment of obstructive sleep apnea may reduce the risk of subsequent dementia. [WATCH TIME: 3 minutes]

Digital Cognitive Behavioral Therapy Response Poorer Among Black Pregnant Women

Among those observed in the trial, Black pregnant women had a mean number of 4.20 sessions of cognitive behavioral therapy compared with 5.54 for White pregnant women.

State of Stem Cell Transplantation for Multiple Sclerosis

Insomnia Severity Index Responders Show Additional Benefits From Lemborexant

In subanalyses of ISI responders with chronic insomnia, those in the lemborexant 10-mg group demonstrated significantly greater changes from baseline in sleep onset latency compared with placebo.

IDSIQ Instrument Sensitive to Daytime Changes Experienced in Insomnia

The IDSIQ showed score changes that correlated with clinically meaningful improvement on various responder definition estimates following triangulation.